Method of making a second olefm using a first olefin, comprising steps (A) and (B): (A) performing a metathesis reaction with the first olefm in the presence of a metal complex configured to catalyse said metathesis reaction; (B) epoxidizing an olefin contained in the reaction mixture obtained in step (A) to form an epoxide; and deoxygenizing said epoxide to form said second olefin.

A method for conversion of a composition containing HCFO-1233zd(Z) and HCFC-244fa to form HCFO-1233zd(E) by reacting a mixture including HCFO-1233zd(Z) and HCFC-244fa in a vapor phase in the presence of a catalyst to simultaneously isomerize HCFC-1233zd(Z) to form HCFO-1233zd(E) and dehydrohalogenate HCFC-244fa to form HCFO-1233zd(E). The catalyst may be a chromium-based catalyst such as chromium trifluoride, chromium oxyfluoride, or chromium oxide, for example.

Compounds and methods related to the prevention and treatment of diseases and conditions, some of which are facilitated by melanogenesis are disclosed. Specifically, the present subject matter includes a series of compounds and compositions and their use for anti-melanogenic and antioxidant activity. This subject matter also includes the treatment of skin disorder due to acne vulgaris and related inflammatory and post inflammatory hyperpigmentation. Methods for synthesizing contemplated compounds are also disclosed.

The present disclosure describes terpenophenolic compounds and their use in medicine. The present disclosure further describes perrottetinene-like compounds, the manufacture thereof, formulations containing same and their use in medicine. Such compounds include (1′R,2′R)-5′-methyl-phenethyl-2′-(prop-1-ene-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-diol (CBD-PET) or (1′R,2′R)-4-(4-hydroxyphenethyl)-5′-methyl-2′-(prop-1-ene-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-diol (CBD-PET-OH).

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

##STR00001##

Method of making a second olefin using a first olefin, comprising steps (A) and (B): (A) performing a metathesis reaction with the first olefin in the presence of a metal complex configured to catalyse said metathesis reaction; (B) epoxidizing an olefin contained in the reaction mixture obtained in step (A) to form an epoxide; and deoxygenizing said epoxide to form said second olefin.

The present invention refers to a mixture of positional isomers of aminaphtone, to an aminaphtone product comprising said mixture and to a new method of high-performance liquid chromatography (HPLC) useful for the characterization of aminaphtone. The method allows to identify in the positional isomers of which the aminaphtone in a product containing them, and can be used to choose lots of aminaphtone suitable for pharmaceutical use.

A skeletal isomerization process for isomerizing olefins is described. The process includes the steps of feeding an olefin-containing feed to a reactor at a space velocity of 1-100 hr.sup.−1 for a first period of time at a first temperature, followed by discontinuing, or stopping, the olefin-containing feed for a second period of time while maintaining the reactor at a second temperature, before resuming the flow of the olefin-containing feed for a third period of time. The methods of this disclosure increase the yield of the skeletal isomers product while reducing the production of C5+ heavy olefins. Additionally, the methods of this disclosure can be applied to feeds containing iso-olefins (for the production of linear olefins) or linear olefins (for the production of iso-olefins).

The present invention relates to a catalyst for isomerization of alkylated aromatics such as mixed xylenes, using xylene isomerization catalyst particles including post-framework modified USY zeolite in which zirconium atoms and/or titanium atoms and/or hafnium atoms form a part of a framework of an ultra-stable Y-type zeolite.

The present disclosure relates to new cannabinoid sulfonate esters and processes for their use to prepare cannabinoids. The disclosure also relates to the use of catalysts and catalytic processes for the preparation of cannabinoids from the cannabinoid sulfonate esters.